CN100412546C - 一种复方丹参滴丸指纹图谱的测定方法 - Google Patents
一种复方丹参滴丸指纹图谱的测定方法 Download PDFInfo
- Publication number
- CN100412546C CN100412546C CNB2005100552633A CN200510055263A CN100412546C CN 100412546 C CN100412546 C CN 100412546C CN B2005100552633 A CNB2005100552633 A CN B2005100552633A CN 200510055263 A CN200510055263 A CN 200510055263A CN 100412546 C CN100412546 C CN 100412546C
- Authority
- CN
- China
- Prior art keywords
- mobile phase
- rsd
- compound
- peak area
- retention time
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 95
- 239000006187 pill Substances 0.000 title claims abstract description 89
- 235000017276 Salvia Nutrition 0.000 title claims abstract description 43
- 238000000034 method Methods 0.000 title abstract description 36
- 240000007164 Salvia officinalis Species 0.000 title description 75
- 238000012360 testing method Methods 0.000 claims abstract description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000000243 solution Substances 0.000 claims abstract description 22
- 238000010828 elution Methods 0.000 claims abstract description 11
- 241001072909 Salvia Species 0.000 claims abstract 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 63
- 239000009524 danshen dripping Substances 0.000 claims description 62
- 239000007864 aqueous solution Substances 0.000 claims description 50
- 229910019142 PO4 Inorganic materials 0.000 claims description 45
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 45
- 239000010452 phosphate Substances 0.000 claims description 45
- 238000002360 preparation method Methods 0.000 claims description 29
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 18
- 238000003556 assay Methods 0.000 claims description 13
- 238000004811 liquid chromatography Methods 0.000 claims description 13
- 239000000945 filler Substances 0.000 claims description 9
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 9
- 239000000377 silicon dioxide Substances 0.000 claims description 9
- 238000005070 sampling Methods 0.000 claims description 7
- TYYVQPXICFOMON-UHFFFAOYSA-N [P].CC#N Chemical compound [P].CC#N TYYVQPXICFOMON-UHFFFAOYSA-N 0.000 claims description 2
- 239000011260 aqueous acid Substances 0.000 claims description 2
- 238000003908 quality control method Methods 0.000 abstract description 9
- 238000004128 high performance liquid chromatography Methods 0.000 abstract description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract description 6
- FGDQGIKMWOAFIK-UHFFFAOYSA-N acetonitrile;phosphoric acid Chemical compound CC#N.OP(O)(O)=O FGDQGIKMWOAFIK-UHFFFAOYSA-N 0.000 abstract description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 abstract description 3
- 238000001514 detection method Methods 0.000 abstract description 3
- 239000012153 distilled water Substances 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 238000002347 injection Methods 0.000 abstract description 2
- 239000007924 injection Substances 0.000 abstract description 2
- 239000008188 pellet Substances 0.000 abstract description 2
- 230000014759 maintenance of location Effects 0.000 description 87
- 239000012071 phase Substances 0.000 description 52
- 235000005412 red sage Nutrition 0.000 description 43
- 239000003814 drug Substances 0.000 description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- 239000000126 substance Substances 0.000 description 35
- 238000010521 absorption reaction Methods 0.000 description 31
- 244000132619 red sage Species 0.000 description 29
- 239000000203 mixture Substances 0.000 description 22
- 241000180649 Panax notoginseng Species 0.000 description 16
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 15
- 235000003143 Panax notoginseng Nutrition 0.000 description 15
- 244000131316 Panax pseudoginseng Species 0.000 description 15
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 15
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 14
- 239000000284 extract Substances 0.000 description 14
- 239000000463 material Substances 0.000 description 12
- 239000000470 constituent Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000007791 liquid phase Substances 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 5
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 5
- 229940116229 borneol Drugs 0.000 description 5
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 5
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 5
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 4
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 4
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- XYKZSUXWBGUGQV-UHFFFAOYSA-N 4,8-dimethylnaphtho[2,1-f][1]benzofuran-7,11-dione Chemical compound CC1=CC=CC2=C(C(C=3OC=C(C=3C3=O)C)=O)C3=CC=C21 XYKZSUXWBGUGQV-UHFFFAOYSA-N 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 description 2
- 244000194101 Ginkgo biloba Species 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 229930183118 Tanshinone Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 2
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 2
- OORMXZNMRWBSTK-LGFJJATJSA-N dammarane Chemical compound C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@H](C)CCCC(C)C)[C@H]4CC[C@@H]3[C@]21C OORMXZNMRWBSTK-LGFJJATJSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008899 fufang danshen Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229960003371 protocatechualdehyde Drugs 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000011122 softwood Substances 0.000 description 2
- 235000020985 whole grains Nutrition 0.000 description 2
- LJEROUHPDCFEGJ-VVTLTYDVSA-N (1r,3r,4s)-4,7,9-trihydroxy-1,3-dimethyl-3,4-dihydro-1h-benzo[g]isochromene-5,10-dione Chemical compound O=C1C2=CC(O)=CC(O)=C2C(=O)C2=C1[C@H](O)[C@@H](C)O[C@@H]2C LJEROUHPDCFEGJ-VVTLTYDVSA-N 0.000 description 1
- XDUXBBDRILEIEZ-LJQANCHMSA-N (6s)-6-(hydroxymethyl)-1,6-dimethyl-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCC[C@](C)(CO)C3=CC=C2C2=C1C(C)=CO2 XDUXBBDRILEIEZ-LJQANCHMSA-N 0.000 description 1
- MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 description 1
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 206010013709 Drug ineffective Diseases 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 235000012364 Peperomia pellucida Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 1
- UMPZKDHDIZUVTO-UHFFFAOYSA-N Salvianolic acid D Natural products Cc1ccc(C=CC(=O)OC(Cc2ccc(O)c(O)c2)C(=O)O)c(CC(=O)O)c1O UMPZKDHDIZUVTO-UHFFFAOYSA-N 0.000 description 1
- KFCMFABBVSIHTB-WUTVXBCWSA-N Salvianolic acid D Chemical compound OC(=O)CC1=C(O)C(O)=CC=C1\C=C\C(=O)O[C@@H](C(O)=O)CC1=CC=C(O)C(O)=C1 KFCMFABBVSIHTB-WUTVXBCWSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- XDUXBBDRILEIEZ-UHFFFAOYSA-N Tanshinone IIB Natural products O=C1C(=O)C2=C3CCCC(C)(CO)C3=CC=C2C2=C1C(C)=CO2 XDUXBBDRILEIEZ-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000029162 bladder disease Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 244000138993 panchioli Species 0.000 description 1
- -1 phenol aldehyde Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000003822 preparative gas chromatography Methods 0.000 description 1
- 229940126532 prescription medicine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000001303 quality assessment method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 1
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 208000026533 urinary bladder disease Diseases 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
Description
峰1 | 峰2 | 峰3 | 峰4 |
丹参素 | 原儿茶醛 | 异紫草酸A | 异紫草酸B |
峰5 | 峰6 | 峰7 | 峰8 |
丹酚酸D | 迷迭香酸 | 丹酚酸B | 丹酚酸A |
峰号 | 平均保留时间 | 保留时间RSD% | 平均峰面积 | 峰面积RSD% | 单峰占总峰面积的百分比 |
1 | 6.12 | 0.83 | 2554.6 | 10.68 | 18.19% |
2 | 10.00 | 0.77 | 4438.6 | 14.63 | 31.61% |
3 | 15.96 | 0.58 | 740.16 | 13.18 | 5.27% |
4 | 17.89 | 1.17 | 667.68 | 13.47 | 4.75% |
5 | 20.27 | 2.94 | 654.73 | 15.01 | 4.66% |
6 | 23.83 | 0.88 | 1140.51 | 16.45 | 8.12% |
7 | 27.67 | 0.61 | 880.14 | 11.49 | 6.27% |
8 | 30.93 | 0.47 | 2965.29 | 10.21 | 21.12% |
峰号 | 平均保留时间 | 保留时间RSD% | 平均峰面积 | 峰面积RSD% | 单峰占总峰面积的百分比 |
1 | 6.04 | 0.31 | 1627.92 | 5.91 | 20.80% |
2 | 9.9 | 0.25 | 2575.54 | 13.53 | 32.90% |
3 | 16.89 | 0.61 | 366.89 | 10.92 | 4.69% |
4 | 17.84 | 0.7 | 381.4 | 13.81 | 4.87% |
5 | 20.31 | 0.96 | 186.08 | 12.04 | 2.38% |
6 | 23.74 | 0.76 | 555.35 | 10.48 | 7.09% |
7 | 27.73 | 0.5 | 281.91 | 18.08 | 3.60% |
8 | 31.02 | 1.18 | 1852.33 | 14.84 | 23.66% |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100552633A CN100412546C (zh) | 2004-03-17 | 2005-03-17 | 一种复方丹参滴丸指纹图谱的测定方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200410018755 | 2004-03-17 | ||
CN200410018755.0 | 2004-03-17 | ||
CNB2005100552633A CN100412546C (zh) | 2004-03-17 | 2005-03-17 | 一种复方丹参滴丸指纹图谱的测定方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1670524A CN1670524A (zh) | 2005-09-21 |
CN100412546C true CN100412546C (zh) | 2008-08-20 |
Family
ID=35041860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100552633A Active CN100412546C (zh) | 2004-03-17 | 2005-03-17 | 一种复方丹参滴丸指纹图谱的测定方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100412546C (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102621265B (zh) * | 2012-03-27 | 2014-09-24 | 贵州景峰注射剂有限公司 | 参芎葡萄糖注射液的多成分含量测定方法 |
CN103424476B (zh) * | 2012-05-25 | 2016-08-17 | 天津天士力之骄药业有限公司 | 同时测定丹参多酚酸中4种水溶性成分的方法 |
CN109406672A (zh) * | 2018-11-20 | 2019-03-01 | 合肥创新医药技术有限公司 | 一种使用hplc测定中药一贯煎的指纹图谱方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002058625A2 (en) * | 2000-12-22 | 2002-08-01 | Tianjin Tasly Pharmaceutical Co., Ltd., China | Herbal composition for angina pectoris, method to prepare same and uses thereof |
CN1470868A (zh) * | 2002-07-26 | 2004-01-28 | 天津市金士力药物研究开发有限公司 | 丹参脂溶性成分指纹图谱的建立方法及其标准图谱 |
CN1141575C (zh) * | 2001-06-29 | 2004-03-10 | 天津市金士力药物研究开发有限公司 | 一种丹参药材的鉴别方法 |
-
2005
- 2005-03-17 CN CNB2005100552633A patent/CN100412546C/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002058625A2 (en) * | 2000-12-22 | 2002-08-01 | Tianjin Tasly Pharmaceutical Co., Ltd., China | Herbal composition for angina pectoris, method to prepare same and uses thereof |
CN1141575C (zh) * | 2001-06-29 | 2004-03-10 | 天津市金士力药物研究开发有限公司 | 一种丹参药材的鉴别方法 |
CN1470868A (zh) * | 2002-07-26 | 2004-01-28 | 天津市金士力药物研究开发有限公司 | 丹参脂溶性成分指纹图谱的建立方法及其标准图谱 |
Non-Patent Citations (6)
Title |
---|
HPLC-DAD法测定复方新脑康软胶囊中5中有效成分含量. 张虹等.中成药,第24卷第4期. 2002 |
HPLC-DAD法测定复方新脑康软胶囊中5中有效成分含量. 张虹等.中成药,第24卷第4期. 2002 * |
HPLC法测定祛斑颗粒中丹参素的含量. 徐从云等.中国新药杂志,第11卷第3期. 2002 |
HPLC法测定祛斑颗粒中丹参素的含量. 徐从云等.中国新药杂志,第11卷第3期. 2002 * |
复方丹参片指纹图谱的质量评价研究. 曾令杰等.广东药学院学报,第18卷第3期. 2002 |
复方丹参片指纹图谱的质量评价研究. 曾令杰等.广东药学院学报,第18卷第3期. 2002 * |
Also Published As
Publication number | Publication date |
---|---|
CN1670524A (zh) | 2005-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100450501C (zh) | 一种治疗心脑血管疾病的中药制剂及其制备方法 | |
CN102028840B (zh) | 一种复方中成药的超高压液相检测方法 | |
CN1141575C (zh) | 一种丹参药材的鉴别方法 | |
CN102100818A (zh) | 霍香正气片的质量控制方法 | |
CN102353735B (zh) | 通脉糖眼明胶囊的质量检测方法 | |
WO2005088295A1 (fr) | Procede de controle de qualite destine aux pilules a avaler composees de danshen | |
CN100381813C (zh) | 复方丹参滴丸质量控制方法 | |
CN100412546C (zh) | 一种复方丹参滴丸指纹图谱的测定方法 | |
CN102068657B (zh) | 中药制剂脉络通的检测方法 | |
CN102539599B (zh) | 一种强肝药物的检测方法 | |
CN100381817C (zh) | 一种复方丹参滴丸质量控制方法 | |
CN1315495C (zh) | 一种丹参提取物、其制备方法、药物制剂及检测方法 | |
CN1850208A (zh) | 一种驴胶补血制剂的质量控制方法 | |
CN103604898B (zh) | 益心舒制剂的指纹图谱检测方法 | |
CN102590423B (zh) | 川芎茶调颗粒制剂指纹图谱的测定方法 | |
CN100442049C (zh) | 复方丹参滴丸指纹图谱的测定方法 | |
CN108226325A (zh) | 葶苈生脉口服液组合物指纹图谱的建立方法 | |
CN109884226A (zh) | 一种杭白芍有效成分的提取方法 | |
CN102507844B (zh) | 血栓心脉宁片的检测方法 | |
CN103316074A (zh) | 一种花锚提取物、黄芪提取物与甘草提取物的组合药物及其制剂、应用 | |
CN109288907B (zh) | 一种延丹胶囊及其制备方法与检测方法及新用途 | |
CN103239506A (zh) | 通脉口服液原料药提取物 | |
CN1059820C (zh) | 一种治心血管病药物的制备方法 | |
CN102309543A (zh) | 复方丹参浓缩制剂及其制备、检测方法 | |
CN101637566A (zh) | 中药制剂中丹参的质量控制方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TIANSHILI PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
CP01 | Change in the name or title of a patent holder |